Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Alligator Bioscience, J&J deal

    Alligator Bioscience AB, Lund, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Alligator granted Johnson & Johnsons Janssen Biotech Inc. unit exclusive, worldwide rights to develop and …

    Published on 8/17/2015
  • Apeiron Biologics, Evotec, Sanofi deal

    Apeiron Biologics AG, Vienna, Austria Evotec AG (Xetra:EVT), Hamburg, Germany Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cancer, Hematology The companies partnered exclusively to identify, develop and …

    Published on 8/17/2015
  • AstraZeneca, Zeria deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Zeria Pharmaceutical Co. Ltd. (Tokyo:4559), Tokyo, Japan Business: Autoimmune Zerias Tillotts Pharma AG unit purchased ex-U.S. rights to Entocort budesonide from …

    Published on 8/17/2015
  • Biomet, Zimmer deal

    Biomet Inc., Warsaw, Ind. Zimmer Holdings Inc., Warsaw, Ind. Business: Musculoskeletal Zimmer Holdings completed its acquisition of fellow musculoskeletal company Biomet for $8.3 billion in cash and 32.7 million Zimmer …

    Published on 8/17/2015
  • Biomics Biotechnologies, Benitec deal

    Biomics Biotechnologies Co. Ltd., Nantong, China Benitec Biopharma Ltd. (ASX:BLT), Sydney, Australia Business: Infectious Benitec purchased Biomics share in DNA-directed RNAi (ddRNAi)-based HBV drug candidate Hepbarna, …

    Published on 8/17/2015
  • Cevec, Biotest deal

    Cevec Pharmaceuticals GmbH, Cologne, Germany Biotest AG (Xetra:BIO), Dreieich, Germany Business: Hematology Cevec granted Biotest rights to the CAPGo platform to develop and commercialize molecules to treat hemophilia. …

    Published on 8/17/2015
  • Cytos, Checkmate Pharma deal

    Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland Checkmate Pharmaceuticals Inc., Cambridge, Mass. Business: Cancer Cytos granted Checkmate exclusive, worldwide rights to its platform technologies for virus-like…

    Published on 8/17/2015
  • Depomed, Horizon Pharma deal

    Depomed Inc. (NASDAQ:DEPO), Newark, Calif. Horizon Pharma plc (NASDAQ:HZNP), Dublin, Ireland Business: Neurology In a letter to Depomeds board, Horizon reaffirmed its revised proposal to acquire Depomed for $33 per …

    Published on 8/17/2015
  • Ecole Polytechnique Federale de Lausanne, TES Pharma deal

    Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland TES Pharma s.r.l., Perugia, Italy Business: Endocrine/Metabolic TES and Ecole Polytechnique Federale de Lausanne (EPFL) partnered to develop small molecule…

    Published on 8/17/2015
  • Endo, EpiCept deal

    Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland EpiCept Corp., Tarrytown, N.Y. Business: Neurology The companies terminated a 2003 deal granting Endo exclusive, worldwide rights to commercialize LidoPain …

    Published on 8/17/2015
  • Evotec, Sanofi deal

    Evotec AG (Xetra:EVT), Hamburg, Germany Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Endocrine/Metabolic The companies partnered to develop and commercialize a stem cell-derived beta cell replacement therapy …

    Published on 8/17/2015
  • EyeGate, Valeant Pharmaceuticals deal

    EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG), Waltham, Mass. Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Business: Ophthalmic EyeGate granted Valeant exclusive rights to develop and …

    Published on 8/17/2015
  • G7 Therapeutics, MorphoSys deal

    G7 Therapeutics AG, Zurich, Switzerland MorphoSys AG (Xetra:MOR;Pink:MPSYF), Martinsried, Germany Business: Antibodies MorphoSys and G7 partnered exclusively to discover, develop and commercialize antibodies against G …

    Published on 8/17/2015
  • Genetrix, TiGenix deal

    Genetrix S.L., Madrid, Spain TiGenix N.V. (Euronext:TIG), Leuven, Belgium Business: Cardiovascular TiGenix acquired Genetrixs Coretherapix S.L. subsidiary for EUR1.2 million ($1.3 million) in cash and EUR5.5 million ($6…

    Published on 8/17/2015
  • GeneWeave, Roche deal

    GeneWeave Biosciences Inc., Los Gatos, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche will acquire GeneWeave for $190 million up front and up to $235 million in milestones. Roche will …

    Published on 8/17/2015
  • GlaxoSmithKline, UCSD deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. University of California San Diego, La Jolla, Calif. Business: Cancer GlaxoSmithKline and the university partnered to treat leukemia and other diseases. The …

    Published on 8/17/2015
  • Incyte, Vanderbilt University deal

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Vanderbilt University, Nashville, Tenn. Business: Autoimmune, Cancer Incyte will fund research with the universitys Vanderbilt-Ingram Cancer Center at Vanderbilt University …

    Published on 8/17/2015
  • Innate Pharma, Institut Paoli-Calmettes deal

    Innate Pharma S.A. (Euronext:IPH), Marseille, France Institut Paoli-Calmettes, Marseille, France Business: Cancer, Pharmacogenetics Innate and the institute partnered to identify biomarkers and populations of patients …

    Published on 8/17/2015
  • Inovio, AstraZeneca deal

    Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer Inovio granted AstraZenecas MedImmune LLC unit exclusive, worldwide rights to develop and …

    Published on 8/17/2015
  • MABLife, ElsaLys Biotech deal

    MABLife S.A.S, Evry, France ElsaLys Biotech, Lyon, France Business: Cancer, Ophthalmic MABLife granted ElsaLys exclusive worldwide rights to develop and commercialize MAT-302. ElsaLys said it will develop two versions …

    Published on 8/17/2015
  • Merck, University of Texas MD Anderson Cancer Center deal

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer, Hepatic, Gastrointestinal Merck and MD Anderson partnered to study Keytruda in combination …

    Published on 8/17/2015
  • Natera, UCL deal

    Natera Inc. (NASDAQ:NTRA), San Carlos, Calif. University College London, London, U.K. Business: Cancer Natera and the University College London Cancer Institute partnered to use Nateras massively multiplexed PCR …

    Published on 8/17/2015
  • Oculeve, Allergan deal

    Oculeve Inc., South San Francisco, Calif. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Ophthalmic Allergan will acquire ophthalmic medical device company Oculeve for $125 million in cash. Oculeve is eligible to …

    Published on 8/17/2015
  • Quantum Genomics, University of Ottawa, Institut National de la Sante et de la Recherche Medicale deal

    Quantum Genomics Corp. (Euronext:ALQGC), Massy, France University of Ottawa, Ottawa, Ontario Institut National de la Sante et de la Recherche Medicale (INSERM), Paris, France Business: Cardiovascular Quantum partnered …

    Published on 8/17/2015
  • Sanofi, Medicines for Malaria Venture deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Medicines for Malaria Venture, Geneva, Switzerland Business: Infectious Sanofi and Medicines for Malaria Venture (MMV) extended by an undisclosed amount of time a May 2011 …

    Published on 8/17/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993